Trial · NCT03672292
Results by group116
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 116
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | SCY-078 Plus Voriconazole | Number of participants with treatment emergent adverse events | 10 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | Voriconazole Mono-therapy | Number of participants with treatment emergent adverse events | 11 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | SCY-078 Plus Voriconazole | Number of participants with treatment-related adverse events | 4 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | Voriconazole Mono-therapy | Number of participants with treatment-related adverse events | 0 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | SCY-078 Plus Voriconazole | Number of participants discontinued due to adverse event | 2 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | Voriconazole Mono-therapy | Number of participants discontinued due to adverse event | 4 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | SCY-078 Plus Voriconazole | Number of participants who died | 3 | participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs), Drug-related Adverse Events (AEs), Discontinuations Due to AEs and Deaths | Voriconazole Mono-therapy | Number of participants who died | 1 | participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | SCY-078 Plus Voriconazole | Participants with Complete or Partial Response at End of Treatment | 7 | Participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | Voriconazole Mono-therapy | Participants with Complete or Partial Response at End of Treatment | 9 | Participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | SCY-078 Plus Voriconazole | Participants with Complete or Partial Response at Day 42 | 4 | Participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | Voriconazole Mono-therapy | Participants with Complete or Partial Response at Day 42 | 6 | Participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | SCY-078 Plus Voriconazole | Participants with Complete or Partial Response at Day 84 | 4 | Participants | |
| Percentage of Participants With Complete Response or Partial Response as Determined by the Data Review Committee (DRC) | Voriconazole Mono-therapy | Participants with Complete or Partial Response at Day 84 | 4 | Participants | |
| Percentage of Participants Who Died (Any Cause) | SCY-078 and Voriconazole | Day 42 | 1 | Participants | |
| Percentage of Participants Who Died (Any Cause) | Voriconazole Mono-Therapy | Day 42 | 1 | Participants | |
| Percentage of Participants Who Died (Any Cause) | SCY-078 and Voriconazole | Day 84 | 3 | Participants | |
| Percentage of Participants Who Died (Any Cause) | Voriconazole Mono-Therapy | Day 84 | 1 | Participants | |
| Change in Serum Galactomannan Index (GMI) | SCY-078 Plus Voriconazole | Week 1 | -0.1870 | Full Range -0.790 to 0.130 | index |
| Change in Serum Galactomannan Index (GMI) | Voriconazole Mono-therapy | Week 1 | -0.4910 | Full Range -1.200 to 0.100 | index |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03672292/results